HIV-2 Envelope/重组艾滋病毒2包膜蛋白_详细资料

产品信息

HIV-2 Envelope/重组艾滋病毒2包膜蛋白

慧嘉生物您实验身边的好伙伴为客户提供“品质的产品”和“质的服务”
AssayBiotech CUSABIO Immunoway Santa Abcam Cst jackson Pierce Sigma Amresco Qiagen Cayman abnova millipore invitrogen merk ebioscience prospec
欢迎广大客户咨询，另有大量宣传海报和小礼品赠送。
网站：www.biohj.com
Q Q：1284882975 382603320

HIV-2 Envelope/重组艾滋病毒2包膜蛋白
产品编号：HIV-140
产品规格：100μg/500μg/1mg

Introduction HIV-1 ａnd HIV-2 appear to package their RNA differently. HIV-1 binds to any appropriate RNA whereas HIV-2 preferentially binds to mRNA which creates the Gag protein itself. This means that HIV-1 is better able to mutate. HIV-2 is transmitted in the same ways as HIV-1: Through exposure to bodily fluids such as blood, semen, tears ａnd vaginal fluids.
Immunodeficiency develops more slowly with HIV-2.
HIV-2 is less infectious in the early stages of the virus than with HIV-1.
The infectiousness of HIV-2 increases as the virus progresses.
Major differences include reduced pathogenicity of HIV-2 relative to HIV-1, enhanced immune control of HIV-2 infection ａnd often some degree of CD4-independence. Despite considerable sequence ａnd phenotypic differences between HIV-1 ａnd 2 envelopes, structurally they are quite similar. Both membrane-anchored proteins eventually form the 6-helix bundles from the N-terminal ａnd C-terminal regions of the ectodomain, which is common to many viral ａnd cellular fusion proteins ａnd which seems to drive fusion.
HIV-1 gp41 helical regions can form more stable 6-helix bundles than HIV-2 gp41 helical regions however HIV-2 fusion occurs at a lower threshold temperature （25°C）, does not require Ca2+ in the medium, is insensitive to treatment of target cells with cytochalasin B, ａnd is not affected by target membrane glycosphingolipid composition.

Description HIV-2 Envelope recombinant- composes all of the reported immunogenic determinants found in gp39. The gene encoding this fusion protein was synthesized using codons optimized for E.coli expression ａnd doesn’t represent a linear HIV-2 envelope sequence. HIV-2 is a non-glycosylated, 135 amino acids polypeptide chain, having a molecular mass of 16,127 Dalton, P.I=5.17.

Source Escherichia Coli.

Physical Appearance Sterile filtered colorless clear solution.

Formulation 50mM Tris-HCL & 6M urea, pH-7.

2 Purity Greater than 95.0% as determined by HPLC analysis ａnd SDS-PAGE.

Stability HIV-2 Envelope protein is shipped at ambient temperature. Upon arrival, Store at -20°C Stable for Five years frozen. One month in solution at room temperature.

Specificity Immunoreactive with all sera of HIV-2 infected individuals.

Applications HIV-2 Envelope antigen in ELISA ａnd Western blots, excellent antigen for early detection of HIV seroconvertors with minimal specificity problems.

Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.

您可能感兴趣的产品

Introduction	HIV-1 ａnd HIV-2 appear to package their RNA differently. HIV-1 binds to any appropriate RNA whereas HIV-2 preferentially binds to mRNA which creates the Gag protein itself. This means that HIV-1 is better able to mutate. HIV-2 is transmitted in the same ways as HIV-1: Through exposure to bodily fluids such as blood, semen, tears ａnd vaginal fluids. Immunodeficiency develops more slowly with HIV-2. HIV-2 is less infectious in the early stages of the virus than with HIV-1. The infectiousness of HIV-2 increases as the virus progresses. Major differences include reduced pathogenicity of HIV-2 relative to HIV-1, enhanced immune control of HIV-2 infection ａnd often some degree of CD4-independence. Despite considerable sequence ａnd phenotypic differences between HIV-1 ａnd 2 envelopes, structurally they are quite similar. Both membrane-anchored proteins eventually form the 6-helix bundles from the N-terminal ａnd C-terminal regions of the ectodomain, which is common to many viral ａnd cellular fusion proteins ａnd which seems to drive fusion. HIV-1 gp41 helical regions can form more stable 6-helix bundles than HIV-2 gp41 helical regions however HIV-2 fusion occurs at a lower threshold temperature （25°C）, does not require Ca2+ in the medium, is insensitive to treatment of target cells with cytochalasin B, ａnd is not affected by target membrane glycosphingolipid composition.
Description	HIV-2 Envelope recombinant- composes all of the reported immunogenic determinants found in gp39. The gene encoding this fusion protein was synthesized using codons optimized for E.coli expression ａnd doesn’t represent a linear HIV-2 envelope sequence. HIV-2 is a non-glycosylated, 135 amino acids polypeptide chain, having a molecular mass of 16,127 Dalton, P.I=5.17.
Source	Escherichia Coli.
Physical Appearance	Sterile filtered colorless clear solution.
Formulation	50mM Tris-HCL & 6M urea, pH-7.
2 Purity	Greater than 95.0% as determined by HPLC analysis ａnd SDS-PAGE.
Stability	HIV-2 Envelope protein is shipped at ambient temperature. Upon arrival, Store at -20°C Stable for Five years frozen. One month in solution at room temperature.
Specificity	Immunoreactive with all sera of HIV-2 infected individuals.
Applications	HIV-2 Envelope antigen in ELISA ａnd Western blots, excellent antigen for early detection of HIV seroconvertors with minimal specificity problems.
Usage	ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.